Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Summary

This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.

Timeline

Start

2006-05-30

Primary completion

2012-03-16

Completion

2012-12-10

Drugs

Indications